Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET

BACKGROUND: Primary and secondary drug resistance to imatinib and sunitinib in patients with gastrointestinal stromal tumors (GISTs) has led to a pressing need for new therapeutic strategies such as drug combinations. Most GISTs are caused by mutations in the KIT receptor, leading to upregulated KIT...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantaleo, Maria Abbondanza, Nicoletti, Giordano, Nanni, Cristina, Gnocchi, Chiara, Landuzzi, Lorena, Quarta, Carmelo, Boschi, Stefano, Nannini, Margherita, Di Battista, Monica, Castellucci, Paolo, Fanti, Stefano, Lollini, Pier Luigi, Bellan, Elena, Castelli, Mauro, Rubello, Domenico, Biasco, Guido
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022678/
https://www.ncbi.nlm.nih.gov/pubmed/21192792
http://dx.doi.org/10.1186/1756-9966-29-173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022678/
https://www.ncbi.nlm.nih.gov/pubmed/21192792
http://dx.doi.org/10.1186/1756-9966-29-173

Ejemplares similares